Navigation Links
BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100)
Date:7/28/2011

NOVATO, Calif., July 28, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced an update on the GALNS Phase 1/2 extension study (MOR-100) in which patients have continued treatment on an ongoing basis.  

Patients originally enrolled in the initial Phase 1/2 study of GALNS (MOR-002) were continued on therapy in a new extension study (MOR-100).  In the MOR-100 study, patients were treated at a 2.0 mg/kg/week dose and have been followed for an additional 24 weeks.  Previously, these patients were dosed at 0.1 mg/kg/week, 1.0 mg/kg/week and 2.0 mg/kg/week for 12 weeks each in the Phase 1/2 study (MOR-002).  Following the dose escalation phase, patients were then dosed at 1.0 mg/kg/week for an additional 36 to 48 weeks as part of the MOR-002 extension, before continuing on to MOR-100.  Taken together, these patients have received GALNS for approximately two years.

"We now have data from MPS IVA patients that have been on GALNS for approximately 2 years and the data continues to look promising," said Hank Fuchs, M.D., Chief Medical Officer of BioMarin.  "Looking at the Phase 1/2 data in totality, we now see that the endurance and pulmonary function improvements are durable and clinically meaningful compared to baseline, and similar in magnitude to what we have observed during the development of Naglazyme and Aldurazyme.  These data are encouraging in regard to the ongoing Phase 3 study in that the benefits of GALNS appear consistently sustained, and no new risks have emerged.  Enrollment in the Phase 3 study is accelerating and its execution is BioMarin's highest product development priority."

Preliminary highlights, including information on patients treated for 24 additional weeks at 2.0 mg/kg/week are provided below.  Data from the extension study will be submitted for presentation at the World
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies
2. BioMarin to Present at the UBS Global Specialty Pharmaceuticals Conference
3. BioMarin to Host First Quarter 2011 Financial Results Conference Call and Webcast on Thursday, April 28 at 5:00 p.m. ET
4. BioMarin to Host Third Quarter 2010 Financial Results Conference Call and Webcast on Thursday, October 28 at 5:00 p.m. ET
5. BioMarin to Present at the Barclays Capital Global Healthcare Conference
6. BioMarins Chief Executive Jean-Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times
7. BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
8. BioMarin to Present at the Morgan Stanley Healthcare Conference
9. BioMarin to Present at the Baird Healthcare Conference
10. BioMarin to Present at the Jefferies Healthcare Conference
11. BioMarin to Present at the Goldman Sachs Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Bio-Techne Corporation (NASDAQ: TECH ) announced today ... serve in a newly created position of Senior Vice ... be responsible for managing the operations of Bio-Techne,s Protein ... in July 2014 and the recently acquired CyVek business. ... ProteinSimple develops and commercializes proprietary systems and consumables that ...
(Date:11/26/2014)... WARREN, N.J. , Nov. 25, 2014  Roka Bioscience, ... focused on providing advanced testing solutions for the detection of ... will present at the Piper Jaffray  26 th Annual ... conference will be held at The New York Palace in ... During this presentation, material information concerning the Company, its operations, ...
(Date:11/24/2014)... UAE, November 24, 2014 Five ... Bin Rashid Al Maktoum Awards for Medical Sciences", in ... Dubai, United Arab Emirates , on 15 December ... , The Carter Center which won the ... actively involved in numerous programs that aim to improve ...
(Date:11/24/2014)... Belgium , Nov. 24, 2014 ... focused on developing diagnostic tests for cancer and other conditions, ... will be presented at the Science for Business BioWin Day ... Belgium . The data come from VolitionRx,s lung cancer ... Pneumology department of the Centre Hospitalier Universitaire (CHU) de Liege ...
Breaking Biology Technology:Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2Five US Winners Among Recipients of Hamdan Medical Awards 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6
... Feb. 2 Cephalon, Inc .,(Nasdaq: ... its option to,license worldwide rights to Lupuzor(TM), an investigational ... the promising interim,results of the ImmuPharma Phase IIb study. ... filings and subsequent commercialization of,the product. , ...
... , the first clinically proven natural stimulator of growth ... a more desirable "first step" approach to pursuing hormonal ... is only available through a ... increase the body,s own production and release of growth ...
... (NYSE Alternext US: CUR) announced today that Richard ... 11th Annual BIO CEO & Investor Conference to ... Waldorf=Astoria Hotel, New York City.(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )Neuralstem,s ... at 10:00 a.m. Eastern Time.The presentation will be ...
Cached Biology Technology:Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor 2Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor 3Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor 4Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor 5Secretropin(R) - Effective, Preferable, Affordable as an Alternative to Injectable Growth Hormone - Gains Momentum 2Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference 2
(Date:11/7/2014)... , November 6, 2014 Leading ... for better mobile security revolutionizing online transactions.  Companies in focus ... Holdings Ltd. (NYSE: BABA ), Google Inc. (NASDAQ: ... ), eBay Inc. (NASDAQ: EBAY ) and MasterCard ... NXTD and NXTDW), a biometric authentication company focused on ...
(Date:11/6/2014)... predator. Except when that predator runs so fast that it ... size, is the fastest creature on Earth. Some of these ... about five miles per hour). The fastest human can do ... the tiger beetle, a person would have to hit 480 ... problem. At peak speeds, everything becomes a blur. They can,t ...
(Date:11/5/2014)... Redmond has dedicated his career to understanding the ... general audience. , As deputy director and regional ... Nevada,s Desert Research Institute, Redmond has more than ... and dissemination of climate data to the general ... in San Francisco on December 15-19, 2014 the ...
Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6The tiger beetle: Too fast to see 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
... ROUGE Antarctica is home to the largest body of ... one thought that life could exist beneath the Antarctic ice ... places, because conditions were believed to be too extreme. However, ... spent a great deal of time in one of the ...
... El Salvador in the September issue of BioScience presents ... and monies sent to family members by emigrants have ... Susanna B. Hecht and Sassan S. Saatchi, employed socioeconomic ... increases in the area of El Salvador covered by ...
... of Illinois at Chicago researchers have identified new ... antibiotics can be delivered to treat infections. ... fighting infections caused by the pathogens which became ... associate director of UIC,s Center for Pharmaceutical Biotechnology ...
Cached Biology News:LSU professor looks for life in and under antarctic ice 2LSU professor looks for life in and under antarctic ice 3Population movements and money remittances spur forest regrowth 2UIC researchers find promising new targets for antibiotics 2
Microlite 2+ Plate, round bottom; an irradiated, high binding surface with enhanced dynamic range, extra high reflectivity and minimal cross talk for low signal luminescent reactions....
... 0-10 psi precision pressure regulator and pressurized syringe ... Faster liquid-switching Steady flow rate Microinjecting ... Can be added to any new ... any third-party manufacturer, even homemade. Connect to house ...
...
... purified polyclonal antibody to the Salmonella Common ... Isolated from a serum pool of goats ... This antibody is broadly reactive to Salmonella ... It has excellent specificity for Group ...
Biology Products: